Literature DB >> 28839976

Extending the survival advantage of ground glass.

Fred Lee1, Bryan M Burt1.   

Abstract

Year:  2017        PMID： 28839976      PMCID： PMC5543011          DOI： 10.21037/jtd.2017.06.83

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

Review 1.  Nodular ground-glass opacity at thin-section CT: histologic correlation and evaluation of change at follow-up.

Authors:  Chang Min Park; Jin Mo Goo; Hyun Ju Lee; Chang Hyun Lee; Eun Ju Chun; Jung-Gi Im
Journal:  Radiographics       Date:  2007 Mar-Apr       Impact factor: 5.333

2.  Comparison of Prognosis of Solid and Part-Solid Node-Negative Adenocarcinoma With the Same Invasive Component Size.

Authors:  Kyung Wook Shin; Sukki Cho; Jin-Haeng Chung; Kyung Won Lee; Choon-Taek Lee; Kwhanmien Kim; Sanghoon Jheon
Journal:  Ann Thorac Surg       Date:  2017-01-25       Impact factor: 4.330

3.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim Geisinger; Yasushi Yatabe; Charles A Powell; David Beer; Greg Riely; Kavita Garg; John H M Austin; Valerie W Rusch; Fred R Hirsch; James Jett; Pan-Chyr Yang; Michael Gould
Journal:  Proc Am Thorac Soc       Date:  2011-09

4.  Correlations between thin-section CT findings, histopathological and clinical findings of small pulmonary adenocarcinomas.

Authors:  Haruhiro Saito; Yoichi Kameda; Kazuo Masui; Shuji Murakami; Tetsuro Kondo; Hiroyuki Ito; Fumihiro Oshita; Masahiro Tsuboi; Tomoyuki Yokose; Kazumasa Noda; Haruhiko Nakayama; Kouzo Yamada
Journal:  Lung Cancer       Date:  2010-06-08       Impact factor: 5.705

5.  A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201).

Authors:  Kenji Suzuki; Teruaki Koike; Takashi Asakawa; Masahiko Kusumoto; Hisao Asamura; Kanji Nagai; Hirohito Tada; Tetsuya Mitsudomi; Masahiro Tsuboi; Taro Shibata; Haruhiko Fukuda; Harubumi Kato
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

6.  Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using high-resolution computed tomography findings.

Authors:  Yasuhiro Tsutani; Yoshihiro Miyata; Takeharu Yamanaka; Haruhiko Nakayama; Sakae Okumura; Shuji Adachi; Masahiro Yoshimura; Morihito Okada
Journal:  J Thorac Cardiovasc Surg       Date:  2012-12-13       Impact factor: 5.209

Review 7.  Radiologic implications of the 2011 classification of adenocarcinoma of the lung.

Authors:  John H M Austin; Kavita Garg; Denise Aberle; David Yankelevitz; Keiko Kuriyama; Hyun-Ju Lee; Elisabeth Brambilla; William D Travis
Journal:  Radiology       Date:  2012-10-15       Impact factor: 11.105

8.  The ground glass opacity component can be eliminated from the T-factor assessment of lung adenocarcinoma.

Authors:  Tomohiro Murakawa; Chihiro Konoeda; Takuya Ito; Yuta Inoue; Atsushi Sano; Kazuhiro Nagayama; Jun Nakajima
Journal:  Eur J Cardiothorac Surg       Date:  2012-10-09       Impact factor: 4.191

9.  Diameter of Solid Tumor Component Alone Should be Used to Establish T Stage in Lung Adenocarcinoma.

Authors:  Bryan M Burt; Ann N Leung; Masahiro Yanagawa; William Chen; Shawn S Groth; Chuong D Hoang; Viswam S Nair; Joseph B Shrager
Journal:  Ann Surg Oncol       Date:  2015-07-31       Impact factor: 5.344

10.  Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters.

Authors:  Mamoru Takahashi; Yoshiki Shigematsu; Makoto Ohta; Hironobu Tokumasu; Tadashi Matsukura; Takashi Hirai
Journal:  J Thorac Cardiovasc Surg       Date:  2013-10-13       Impact factor: 5.209
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.